- Home
- FLX vs OMER Comparison
FLX vs OMER Comparison
Compare FLX & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLX
- OMER
- Stock Information
- Founded
- FLX 2013
- OMER 1994
- Country
- FLX China
- OMER United States
- Employees
- FLX N/A
- OMER N/A
- Industry
- FLX
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- FLX
- OMER Health Care
- Exchange
- FLX NYSE
- OMER Nasdaq
- Market Cap
- FLX 603.7M
- OMER 530.2M
- IPO Year
- FLX 2024
- OMER 2009
- Fundamental
- Price
- FLX $8.18
- OMER $9.13
- Analyst Decision
- FLX
- OMER Buy
- Analyst Count
- FLX 0
- OMER 4
- Target Price
- FLX N/A
- OMER $22.50
- AVG Volume (30 Days)
- FLX 18.3K
- OMER 509.4K
- Earning Date
- FLX 02-27-2025
- OMER 03-31-2025
- Dividend Yield
- FLX N/A
- OMER N/A
- EPS Growth
- FLX N/A
- OMER N/A
- EPS
- FLX 0.19
- OMER N/A
- Revenue
- FLX $663,142,775.00
- OMER N/A
- Revenue This Year
- FLX N/A
- OMER N/A
- Revenue Next Year
- FLX N/A
- OMER N/A
- P/E Ratio
- FLX $45.81
- OMER N/A
- Revenue Growth
- FLX 1.31
- OMER N/A
- 52 Week Low
- FLX $6.50
- OMER $2.61
- 52 Week High
- FLX $21.95
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- FLX N/A
- OMER 50.45
- Support Level
- FLX N/A
- OMER $8.28
- Resistance Level
- FLX N/A
- OMER $9.08
- Average True Range (ATR)
- FLX 0.00
- OMER 0.58
- MACD
- FLX 0.00
- OMER -0.05
- Stochastic Oscillator
- FLX 0.00
- OMER 62.58
About FLX BINGEX LIMITED SPON ADS EACH REPR 3 CL A ORD SHS
BingEx Ltd provides on-demand dedicated courier services for individual and business customers with superior time certainty, delivery safety and service quality. The company brands its services as FlashEx, which means delivery in a flash. The Group's principal operations and geographic markets are in the People's Republic of China (PRC).
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.